



Cogstate Limited  
ABN 80 090 975 723

Level 2, 255 Bourke Street  
Melbourne Victoria 3000  
Australia

P +61 3 9664 1300  
F +61 3 9664 1301  
W [cogstate.com](http://cogstate.com)

## ASX Announcement 11 December 2019

### Company Secretary Appointment and Resignation

Cogstate Ltd (ASX:CGS), is pleased to announce the appointment of Keith Hawkins as Company Secretary. Keith replaces Claire Newstead-Sinclair, who has resigned from the Company, effective 20 December 2019, to take up a career opportunity that will allow greater flexibility with her young family.

Prior to joining Cogstate, Keith worked as the Director of Finance for RedR Australia Ltd. Mr Hawkins is a member of Certified Practising Accountants (CPA) Australia and holds a Bachelor of Business degree. Keith has over 30 years senior accounting and finance experience predominately working for multi-national companies including Eaton Corporation and Honeywell International in Asia-Pacific based management roles.

In announcing Ms Newstead-Sinclair's departure, CEO Brad O'Connor said, "Claire has been an outstanding contributor to the business over many years. We wish Claire every success in her new role and thank her for her dedicated service to the company, our shareholders, customers and employees."

This announcement was authorised for release by the Cogstate Board.

#### About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For nearly 20 years, Cogstate has proudly supporting the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate has recently entered into an exclusive licensing agreement with pharmaceutical company, Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. For more information, please visit [www.cogstate.com](http://www.cogstate.com).

#### For more information contact:

Brad O'Connor  
Cogstate Chief Executive Officer  
+613 9664 1300 or 0411 888 347  
[boconnor@cogstate.com](mailto:boconnor@cogstate.com)